WHO commits to source drugs and vaccines from 'green' suppliers

By Gareth Macdonald contact

- Last updated on GMT

iStock/Pogonici
iStock/Pogonici

Related tags: World health organization

The WHO has agreed to source drugs from manufacturers which use sustainable production methods.

UN agencies procure more than $3bn (€2.8bn) worth of medicines – generic anti-retroviral drugs, malaria and tuberculosis treatments and vaccines – from manufacturers for their healthcare programmes each year.

This week, the World Health Organization (WHO) joined other UN agencies by agreeing​ to source from producers the use “green” methods. The Geneva, Switzerland-based agency said the move sends an important message to suppliers and manufacturers.

Spokesman Gregory Härtl told us it is “a broad and high-level commitment to the sustainable development principles we all have agreed to espouse in the context of our procurement practices and in the context of our engagement with suppliers.

We would expect that manufacturers would strive to adopt sustainable practices as called for under SDG12​.”

Härtl added that although the WHO has not yet had feedback from industry, “interest in this topic has been communicated to industry suppliers and manufacturers by the WHO and the other signatories, for example at the annual UN Global Supplier meetings​.”

Industry pressure

The commitment is in keeping with other industry-focused WHO policies like the active pharmaceutical ingredient (API) prequalification programme​ which, in part, encourages suppliers to improve standards by promising access to regulated markets.

It also fits with other initiatives. In 2014​, for example, the organization sought to encourage the pharmaceutical industry to invest in the development of treatments for diseases predominantly impacting people in the developing world – including Zika virus.

The same year​, the World Health Assembly - the decision making body of the WHO - called on industry and Governments to control drug prices to make them more accessible to patients.

More recently​, the WHO has been examining the economics of the vaccine market in a bid to find ways of improving access to sustainably produced vaccines in low and middle income countries.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us

Products

View more

Webinars